<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04884035</url>
  </required_header>
  <id_info>
    <org_study_id>CC-220-DLBCL-001</org_study_id>
    <secondary_id>2020-005705-71</secondary_id>
    <nct_id>NCT04884035</nct_id>
  </id_info>
  <brief_title>Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma</brief_title>
  <official_title>A Phase 1b, Open Label, Global, Multicenter, Dose Determination, Randomized Dose Expansion Study to Determine the Maximum Tolerated Dose, Assess the Safety and Tolerability, Pharmacokinetics and Preliminary Efficacy of Iberdomide (CC-220) in Combination With R-CHOP-21 and CC-99282 in Combination With R-CHOP-21 for Subjects With Previously Untreated, Poor Risk (IPI 3 to 5), Aggressive B-cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celgene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Celgene</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1b study consisting of 2 parts: a dose escalation (Part 1) of CC-220 or&#xD;
      CC-99282 added to the standard R-CHOP-21 regimen for first-line treatment of a-BCL. The dose&#xD;
      escalation (Part 1) will consist of 2 parallel arms in combination with Rituximab,&#xD;
      Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP-21); CC-220 and R-CHOP-21&#xD;
      or CC-99282 and R-CHOP-21. Part 1 will be followed by a randomized dose expansion (Part 2)&#xD;
      with CC-220 and/or CC-99282 at the Recommended Phase 2 Dose (RP2D) in combination with&#xD;
      R-CHOP-21.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 15, 2021</start_date>
  <completion_date type="Anticipated">March 16, 2026</completion_date>
  <primary_completion_date type="Anticipated">February 10, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD) - Part 1</measure>
    <time_frame>During the first two cycles of treatment (each cycle is 21 days)</time_frame>
    <description>Frequency of dose-limiting toxicities (DLT) associated with addition of iberdomide (CC-220) to R-CHOP-21 therapy and the addition of CC-99282 to R-CHOP-21 therapy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Recommended Phase 2 Dose (RP2D) - Part 1</measure>
    <time_frame>During the first two cycles of treatment (each cycle is 21 days)</time_frame>
    <description>Defined as the dose that will be selected for dose expansion based on MTD</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of CC-220 and CC-99282 at RP2D - Part 2</measure>
    <time_frame>From the first dose of any IP until 28 days after the last dose of IP</time_frame>
    <description>AEs evaluated using NCI CTCAE criteria, v. 5.0, including treatment -emergent adverse events (TEAEs) and laboratory assessments</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Best overall response rate (ORR)</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>The proportion of participants with best overall response achieved during the study as either Complete Response or Partial Response before subsequent anti-lymphoma therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete Metabolic Response Rate (CMRR)</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>The proportion of participants experiencing complete metabolic response (CMR) before receiving any subsequent anti-lymphoma therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Response (TTR)</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>The time from entry to the study (enrollment date for Part 1 and randomization date for Part 2) to the date of first documented response (≥ PR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>The time from the earliest date of documented response (≥ PR) to the first occurrence of relapse or progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival (PFS)</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>The time from entry to the study (enrollment date for Part 1 and randomization date for Part 2) to the first occurrence of disease progression or death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>The time from entry to the study (enrollment date for Part 1 and randomization date for Part 2) to death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events (AEs)</measure>
    <time_frame>From enrollment until at least 28 days after completion of study treatment</time_frame>
    <description>An AE is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a participant during the course of a study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the participant's health, including laboratory test values regardless of etiology. Any worsening (ie, any clinically significant adverse change in the frequency or intensity of a preexisting condition) should be considered an AE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - Cmax for CC-220</measure>
    <time_frame>At Cycle 1 Day 7 and Cycle 2 Day 7 (each cycle is 21 days)</time_frame>
    <description>Maximum plasma concentration of drug</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - Ctrough for CC-220</measure>
    <time_frame>At Cycle 1 Day 7 and Cycle 2 Day 7 (each cycle is 21 days)</time_frame>
    <description>Minimum or trough concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - AUC for CC-220</measure>
    <time_frame>At Cycle 1 Day 7 and Cycle 2 Day 7 (each cycle is 21 days)</time_frame>
    <description>Area under the plasma concentration-time curve</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - tmax for CC-220</measure>
    <time_frame>At Cycle 1 Day 7 and Cycle 2 Day 7 (each cycle is 21 days)</time_frame>
    <description>Time to maximum plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - t½ for CC-220</measure>
    <time_frame>At Cycle 1 Day 7 and Cycle 2 Day 7 (each cycle is 21 days)</time_frame>
    <description>Terminal elimination half-life in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - CL/F for CC-220</measure>
    <time_frame>At Cycle 1 Day 7 and Cycle 2 Day 7 (each cycle is 21 days)</time_frame>
    <description>Apparent total plasma clearance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - V/F for CC-220</measure>
    <time_frame>At Cycle 1 Day 7 and Cycle 2 Day 7 (each cycle is 21 days)</time_frame>
    <description>Apparent volume of distribution</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - Cmax for CC-99282</measure>
    <time_frame>At Cycle 1 Day 7 and Cycle 2 Day 7 (each cycle is 21 days)</time_frame>
    <description>Maximum plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - Ctrough for CC-99282</measure>
    <time_frame>At Cycle 1 Day 7 and Cycle 2 Day 7 (each cycle is 21 days)</time_frame>
    <description>Minimum or trough concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - AUC for CC-99282</measure>
    <time_frame>At Cycle 1 Day 7 and Cycle 2 Day 7 (each cycle is 21 days)</time_frame>
    <description>Area under the plasma concentration-time curve</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - tmax for CC-99282</measure>
    <time_frame>At Cycle 1 Day 7 and Cycle 2 Day 7 (each cycle is 21 days)</time_frame>
    <description>Time to maximum plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - t½ for CC-99282</measure>
    <time_frame>At Cycle 1 Day 7 and Cycle 2 Day 7 (each cycle is 21 days)</time_frame>
    <description>Terminal elimination half-life in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - CL/F for CC-99282</measure>
    <time_frame>At Cycle 1 Day 7 and Cycle 2 Day 7 (each cycle is 21 days)</time_frame>
    <description>Apparent total plasma clearance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - V/F for CC-99282</measure>
    <time_frame>At Cycle 1 Day 7 and Cycle 2 Day 7 (each cycle is 21 days)</time_frame>
    <description>Apparent volume of distribution</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">76</enrollment>
  <condition>Lymphoma, B-Cell</condition>
  <arm_group>
    <arm_group_label>Administration of CC-220 with R-CHOP-21</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CC-220 to be administered orally in combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP-21) for 6 cycles of treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Administration of CC-99282 with R-CHOP-21</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CC-99282 to be administered orally in combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP-21) for 6 cycles of treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CC-220</intervention_name>
    <description>CC-220 by mouth at the assigned dose starting on Day 1 for 14 consecutive days of the 21-day treatment cycle for 6 cycles of treatment.</description>
    <arm_group_label>Administration of CC-220 with R-CHOP-21</arm_group_label>
    <other_name>Iberdomide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Rituxan 375 mg/m2 on Day 1 by intravenous (IV) infusion or 1400 mg (SC) subcutaneous (from Cycle 2) of a 21-day treatment cycle for up to a total of 6 cycles</description>
    <arm_group_label>Administration of CC-220 with R-CHOP-21</arm_group_label>
    <arm_group_label>Administration of CC-99282 with R-CHOP-21</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Cyclophosphamide 750mg/m2 on Day 1 by IV infusion of a 21-day treatment cycle for up to a total of 6 cycles</description>
    <arm_group_label>Administration of CC-220 with R-CHOP-21</arm_group_label>
    <arm_group_label>Administration of CC-99282 with R-CHOP-21</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>Doxorubicin 50 mg/m2 IV infusion on Day 1 of a 21-day treatment cycle for up to a total of 6 cycles</description>
    <arm_group_label>Administration of CC-220 with R-CHOP-21</arm_group_label>
    <arm_group_label>Administration of CC-99282 with R-CHOP-21</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine</intervention_name>
    <description>Vincristine 1.4 mg/m2 (maximum of 2.0 mg total) IV intravenous on Day 1 of a 21-day treatment cycle for up to a total of 6 cycles</description>
    <arm_group_label>Administration of CC-220 with R-CHOP-21</arm_group_label>
    <arm_group_label>Administration of CC-99282 with R-CHOP-21</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>Prednisone 100 mg PO on Days 1 through 5 of each 21-day treatment or 100mg IV on Day 1 is also acceptable for up to a total of 6 cycles</description>
    <arm_group_label>Administration of CC-220 with R-CHOP-21</arm_group_label>
    <arm_group_label>Administration of CC-99282 with R-CHOP-21</arm_group_label>
    <other_name>Prednisolone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CC-99282</intervention_name>
    <description>CC-99282 by mouth at the assigned dose starting on Day 1 for 7 consecutive days of the 21-day treatment cycle for 6 cycles of treatment.</description>
    <arm_group_label>Administration of CC-99282 with R-CHOP-21</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants must satisfy the following criteria to be enrolled in the study:&#xD;
&#xD;
               1. Is ≥ 18 years of age at the time of signing the informed consent form (ICF).&#xD;
&#xD;
               2. Participant has histologically confirmed (per local evaluation) diagnosis of de&#xD;
                  novo, previously untreated, a-BCL according to 2016 WHO classification.&#xD;
&#xD;
               3. Participant has poor-risk disease defined as International Prognostic Index (IPI)&#xD;
                  score ≥ 3 (high-intermediate or high-risk).&#xD;
&#xD;
               4. Participants must have measurable disease defined by at least one FDG-avid lesion&#xD;
                  for FDGavid subtype and one bi-dimensionally measurable (&gt; 1.5 cm in longest&#xD;
                  diameter) disease by computed tomography (CT) or magnetic resonance imaging&#xD;
                  (MRI), as defined by the Lugano classification (Cheson, 2014).&#xD;
&#xD;
               5. Participant has an Eastern Cooperative Oncology Group (ECOG) performance status&#xD;
                  of 0, 1, or 2.&#xD;
&#xD;
               6. Participants must have the following laboratory values:&#xD;
&#xD;
                    1. Absolute neutrophil count (ANC) ≥ 1.5 x 109/L or ≥ 1.0 x 109/L in case of&#xD;
                       documented bone marrow involvement (&gt; 50% or tumor cells), without growth&#xD;
                       factor support for 7 days (14 days if peg-G-CSF)&#xD;
&#xD;
                    2. Hemoglobin (Hb) ≥ 8 g/dL&#xD;
&#xD;
                    3. Platelets (PLT) ≥ 75 x 109/L or ≥ 50 x 109/L in case of documented bone&#xD;
                       marrow involvement (&gt;50% or tumor cells), without transfusion for 7 days&#xD;
&#xD;
                    4. Aspartate aminotransferase / serum glutamic oxaloacetic transaminase&#xD;
                       (AST/SGOT) and alanine aminotransferase / serum glutamate pyruvic&#xD;
                       transaminase (ALT/SGPT) ≤ 2.5 x upper limit of normal (ULN). In the case of&#xD;
                       documented liver involvement by lymphoma, ALT/SGPT and AST/SGOT must be ≤&#xD;
                       5.0 x ULN.&#xD;
&#xD;
                    5. Serum total bilirubin ≤ 2.0 mg/dL except in cases of Gilbert syndrome, then&#xD;
                       ≤ 5.0 mg/dl&#xD;
&#xD;
                    6. Estimated serum creatinine clearance of ≥ 50 mL/min&#xD;
&#xD;
               7. All participants must:&#xD;
&#xD;
                    1. Have an understanding that the study drug could have a potential teratogenic&#xD;
                       risk.&#xD;
&#xD;
                    2. Agree to follow all requirements defined in the Pregnancy Prevention Program&#xD;
                       for CC-220 or CC-99282 Pregnancy Prevention Plan for Participants in&#xD;
                       Clinical trials.&#xD;
&#xD;
               8. Females of childbearing potential (FCBP) must:&#xD;
&#xD;
                  a. Have two negative pregnancy tests as verified by the investigator prior to&#xD;
                  starting study therapy.&#xD;
&#xD;
               9. Male participants must:&#xD;
&#xD;
                    1. Practice true abstinence or agree to use a condom during sexual contact with&#xD;
                       a pregnant female or a female of childbearing potential while participating&#xD;
                       in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The presence of any of the following will exclude a participant from enrollment:&#xD;
&#xD;
               1. Any significant medical condition, active infection (including SARS-CoV-2&#xD;
                  suspected or confirmed), laboratory abnormality, or psychiatric illness that&#xD;
                  would prevent the participant from participating in the study.&#xD;
&#xD;
               2. Any condition including the presence of laboratory abnormalities, which places&#xD;
                  the participant at unacceptable risk if he/she were to participate in the study.&#xD;
&#xD;
               3. Any other subtype of lymphoma.&#xD;
&#xD;
               4. Documented or suspected CNS involvement by lymphoma.&#xD;
&#xD;
               5. Persistent diarrhea or malabsorption ≥ Grade 2 (NCI CTCAE v5.0), despite medical&#xD;
                  management.&#xD;
&#xD;
               6. Peripheral neuropathy ≥ Grade 2 (NCI CTCAE v5.0).&#xD;
&#xD;
               7. Chronic systemic immunosuppressive therapy or corticosteroids&#xD;
&#xD;
               8. Impaired cardiac function or clinically significant cardiac disease, including&#xD;
                  any of the following:&#xD;
&#xD;
                  a. Left ventricular ejection fraction (LVEF) &lt; 45% as determined by multigated&#xD;
                  acquisition scan (MUGA) or echocardiogram (ECHO)&#xD;
&#xD;
               9. Major surgery ≤ 2 weeks prior to starting CC-220 or CC-99282; participant must&#xD;
                  have recovered from any clinically significant effects of recent surgery.&#xD;
&#xD;
              10. Any condition causing inability to swallow tablets.&#xD;
&#xD;
              11. Known seropositivity for or active viral infection with human immunodeficiency&#xD;
                  virus (HIV)&#xD;
&#xD;
              12. Known chronic active hepatitis B (hepatitis B surface antigen [HBsAg] positive&#xD;
                  and/or hepatitis B core antibody [anti-HBc] positive with viral DNA positive) or&#xD;
                  C (positive serology requiring treatment and/or with evidence of liver damage)&#xD;
                  infection&#xD;
&#xD;
              13. History of other malignancy, unless being free of the disease for ≥ 3 years;&#xD;
                  exceptions to the ≥ 3-year time limit include history of the following:&#xD;
&#xD;
                    1. Localized nonmelanoma skin cancer&#xD;
&#xD;
                    2. Carcinoma in situ of the cervix&#xD;
&#xD;
                    3. Carcinoma in situ of the breast&#xD;
&#xD;
                    4. Incidental histologic finding of prostate cancer (T1a or T1b as per Tumor&#xD;
                       Node Metastasis [TNM] staging system) or prostate cancer that has been&#xD;
                       treated with curative intent.&#xD;
&#xD;
              14. Hypersensitivity to the active substance or to murine proteins, or to any of the&#xD;
                  other excipients of rituximab.&#xD;
&#xD;
              15. Known hypersensitivity to any component of CHOP regimen.&#xD;
&#xD;
              16. Known allergy to thalidomide, pomalidomide, or lenalidomide.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Recruiting sites have contact information. Please contact the sites directly. If there is no contact information,</last_name>
    <phone>please email:</phone>
    <email>Clinical.Trials@bms.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>First line of the email MUST contain the NCT # and Site #.</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mayo Clinic - Arizona</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic - Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Nebraska - Fred and Pamela Buffet Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77003</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Austin Health - Austin Hospital</name>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <zip>3084</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Calvary Mater New Castle</name>
      <address>
        <city>Waratah</city>
        <zip>NSW</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>3080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy</name>
      <address>
        <city>Czestochowa</city>
        <zip>42-202</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Uniwersyteckie Centrum Kliniczne</name>
      <address>
        <city>Gdansk</city>
        <zip>80-952</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>MCM Krakow - PRATIA - PPDS</name>
      <address>
        <city>Slomniki</city>
        <zip>32-090</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Germans Trias i Pujol ICO Badalona</name>
      <address>
        <city>Barcelona</city>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>H. Virgen de la Victoria</name>
      <address>
        <city>Málaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitario de Salamanca - Hospital Clinico</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>China Medical University Hospital</name>
      <address>
        <city>Taichung</city>
        <zip>404332</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Taichung Veterans General Hospital</name>
      <address>
        <city>Taichung</city>
        <zip>407219</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>100229</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Korea, Republic of</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 7, 2021</study_first_submitted>
  <study_first_submitted_qc>May 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 12, 2021</study_first_posted>
  <last_update_submitted>November 4, 2021</last_update_submitted>
  <last_update_submitted_qc>November 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Iberdomide</keyword>
  <keyword>CC-220</keyword>
  <keyword>CC-99282</keyword>
  <keyword>Phase 1</keyword>
  <keyword>B-Cell Lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Vincristine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Information relating to our policy on data sharing and the process for requesting data can be found at the following link:&#xD;
https://www.celgene.com/research-development/clinical-trials/clinical-trials-data-sharing/</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>See Plan Description</ipd_time_frame>
    <ipd_access_criteria>See Plan Description</ipd_access_criteria>
    <ipd_url>https://www.celgene.com/research-development/clinical-trials/clinical-trials-data-sharing/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

